Source: Eur Respir J 2017; 49(1): 1602201; DOI: 10.1183/13993003.02201-2016
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Peter M.A. Calverley. Through a glass darkly: inhaled corticosteroids, airway inflammation and COPD. Eur Respir J 2017; 49(1): 1602201; DOI: 10.1183/13993003.02201-2016

Member's Comments

No comment yet.

Related content which might interest you: Airway inflammation and inhaled corticosteroids in COPD Source: Eur Respir J, 49 (6) 1700289; 10.1183/13993003.00289-2017 Year: 2017 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017 Year: 2017 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016 Year: 2017 Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma Source: Eur Respir J 2006; 27: 172-187 Year: 2006 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004 Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids Source: Eur Respir J 2002; 20: 1364-1369 Year: 2002 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011 COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition Source: Eur Respir J 2006; 27: 863-865 Year: 2006 Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol Source: International Congress 2019 – Airway physiology Year: 2019 Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma Source: Eur Respir J 2001; 18: 444-450 Year: 2001 Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison Source: Eur Respir J 2007; 30: 653-661 Year: 2007 Response to inhaled corticosteroids in patients with non-asthmatic eosinophilic bronchitis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Source: Eur Respir J 2007; 29: 906-913 Year: 2007 Effect of inhaled salt-bromide-iodine thermal water on airway inflammation in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004 Effects of corticosteroids on airway inflammation in cough variant asthma Source: Annual Congress 2004 - Understanding airway regulation by airway monitoring Year: 2004 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Source: Eur Respir J 2006; 27: 1168-1174 Year: 2006